Patent ID: 8530155
Filing Date: 2013-09-10
Classification: C12Q

Abstract:
1. A method for diagnosing common acute lymphoblastic leukemia (cALL) in a subject by distinguishing between normal and common acute lymphoblastic leukemic (cALL) cells, wherein the method comprises the steps of: (a) providing a test sample comprising CD+19 B cells from blood, bone marrow or bone marrow-derived lymphoblasts obtained from said subject; (b) providing an array consisting of 30 to 200 polynucleotide probes complementary to a set of test genes, wherein at least 30 of said probes are complementary to cALL specific target genes set forth in Tables 17A and 17B; (c) using the array of step (b) to calculate the quantity of mRNA corresponding to said test genes and thus determine the expression of the test genes in said test sample, (d) comparing the expression of said test genes in said test sample to the expression of said genes in a control sample consisting essentially of purified B cells derived from a healthy individual; (e) characterizing a cALL specific target gene as dysregulated in the test sample as compared to the control sample if either (a) said target gene is set forth in Table 17A and its expression increases by a factor of 2 or more, or (b) said target gene is set forth in Table 17B and its expression decreases by a factor of 2 or more; and (f) diagnosing said subject with cALL if at least 60% of said cALL specific target genes are identified as dysregulated.